Itraconazole decreases renal clearance of digoxin

Therapeutic Drug Monitoring

Volumn 19, Issue 6, 1997, Pages 609-613

  Jalava, Kirsi Maija ^a   Partanen, Juhani ^b   Neuvonen, Pertti J ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

Clearance; Digoxin; Interaction; Itraconazole; Pharmacokinetics

Indexed keywords

DIGOXIN; ITRACONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; ANTI-ARRHYTHMIA AGENTS; ANTIFUNGAL AGENTS; CROSS-OVER STUDIES; DIGOXIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; ITRACONAZOLE; KIDNEY; MALE; METABOLIC CLEARANCE RATE;

EID: 0031443240     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199712000-00001     Document Type: Article

References (29)

1. Partanen J, Jalava K-M, Neuvonen PJ. Itraconazole increases serum digoxin concentration. Pharmacol Toxicol 1996;79:274-6.
2. Rex J. Itraconazole-digoxin interaction (letter). Ann Intern Med 1992;116:525.
3. Kauffman CA, Bagnasco FA. Digoxin toxicity associated with itraconazole therapy (letter). Clin Infect Dis 1992;15:886-7.
4. Sachs MK, Blanchard LM, Green PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993;16:400-3.
5. Alderman CP, Jersmann HPA. Digoxin-itraconazole interaction (letter). Med J Aust 1993;159:838-9.
6. McClean KL, Sheehan GJ. Interaction between itraconazole and digoxin (letter). Clin Infect Dis 1994;18:259-60.
7. Jalava K-M, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997;61:410-5.
8. Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
9. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
10. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
11. Pohjola-Sintonen S, Viitasalo M, Toivonen L, et al. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45: 191-3.
12. Allenmark S, Edebo A, Lindgren K. Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence determination. J Chromatogr 1990;532:203-6.
13. Remmel RP, Dombrovskis D, Canafax DM. Assay of itraconazole in leukaemic patient plasma by reversed-phase small-bore liquid chromatography. J Cromatogr 1988;432:388-94.
14. Dollery C, ed. Therapeutic drugs, vol. 1. Edinburgh: Churchill Livingstone, 1991:D125-32.
15. Lindebaum J, Rund DG, Butler VP, et al. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981;305:789-94.
16. de Lannoy IAM, Silverman M. The mdr-1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Comm 1992;189:551-7.
17. Lum BL, Gosland MP. MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 1995;9:319-36.
18. Kurosawa M, Okabe M, Hara N, et al. Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukaemia cells. Ann Hematol 1996;72:17-21.
19. Caldwell JH, Cline CT. Biliary excretion of digoxin in man. Clin Pharmacol Ther 1976;19:410-5.
20. Berndt A, Grametté T, Kirch W. Digoxin-erythromycin interaction: in vitro evidence for competition for intestinal P-glycoprotein [abstract]. J Clin Pharmacol 1996;36:848.
21. Hedman A, Angelin B, Arvidsson A, et al. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 1991;49:256-62.
22. de Lannoy IAM, Koren G, Klein J, et al. Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am J Physiol 1992;263:F613-22.
23. Schenk-Gustafsson K, Juhlin-Dannfelt A, Dahlqvist R. Renal function and digoxin clearance during quinidine therapy. Clin Physiol 1982;2:401-8.
24. Cohen AF, Kroon R, Schoemaker R, et al. Influence of gastric acidity on the bioavailability of digoxin. Ann Intern Med 1991; 115:540-5.
25. Gault H, Kalra J, Ahmed M, et al. Influence of gastric pH on digoxin biotransformation. II. Extractable urinary metabolites. Clin Pharmacol Ther 1981;29:181-90.
26. Gault MH, Sugden D, Maloney C, et al. Biotransformation and elimination of digoxin with normal and minimal renal function. Clin Pharmacol Ther 1979;25:499-513.
27. Lacarelle B, Rahmani R, deSousa G, et al. Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam Clin Pharmacol 1991;5:567-82.
28. Dodds HM, Norris RLG, Johnson AG, et al. Evaluation and comparison of the TDxII, Stratus, and OPUS digoxin assays. Ther Drug Monit 1995;17:68-74.
29. Abbot Laboratories, IL. TDxFLx TDx assays manual. Digoxin II, 1993:1-6.